An Open-Label Multicenter Study in Metastatic Castrate-Resistant Prostate Cancer Patients Previously Treated with Sipuleucel-T on Dendreon Study P-11.

Objective

This study plans to learn more about Sipuleucel-T which is an immune system treatment for prostate cancer that is administered via IV.

IRB Protocol Number

11-1335

Principal Investigator(s)

L. MICHAEL GLODE

Cancer Trials

• Prostate Cancer

Sponsor(s)

DENDREON CORPORATION

Contact

NICOLE CHRONISTER at 720-848-0602
or NICOLE.CHRONISTER@ucdenver.edu

Eligibility and Other Participant Information

What To Expect : Treatment will follow a screening period that takes place to determine eligibility, and will last for 12 months. You will enter the long term follow-up phase of the study after the Month 12 Visit. // Eligibility criteria include but are not limited to: 18 years or older in Metastatic Castrate-Resistant Prostate Cancer Patients Previously Treated with Sipuleucel-T on Dendreon Study P-11.